<DOC>
	<DOCNO>NCT00887315</DOCNO>
	<brief_summary>Primary goal study ass overall survival addition hypofractionated image guide radiotherapy concurrently Docetaxel cisplatin . Survival assess 1 year date study enrollment date death .</brief_summary>
	<brief_title>The Synergistic Metastases Annihilation With Radiotherapy Docetaxel ( Taxotere ) SMART Trial Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Age 18 year old 2 . Life expectancy &gt; 6 month 3 . Histologically cytologically confirm diagnosis NSCLC 4 . Patients AJCC stage IV cancer distant metastasis without malignant pleural pericardial effusion diagnosis start study 1 . Patients pleural effusion transudative , cytologically negative , nonbloody eligible long stable impair ability define tumor volume . 2 . If pleural effusion small diagnostic thoracentesis , patient eligible . 5 . Primary regional nodal disease encompassable reasonable radiotherapy portal : 6 . Patients 15 site disease amenable RT therapy see standard imaging ( CT , MRI , bone scan , PET scan ) 7 . Unidimensionally measurable disease ( base RECIST ) desirable strictly require . 8 . Patients brain metastasis allow long meet inclusion criterion . Brain metastasis must treat whole brain radiotherapy stereotactic radiosurgery surgical resection follow whole brain radiotherapy . 9 . ECOG performance status &lt; 2 10 . No prior RT currently involve tumor site 11 . Baseline peripheral neuropathy &lt; grade 1 12 . Room air saturation ( SaO2 ) &gt; 90 % 13 . Patients must normal organ marrow function 14 . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . 15 . Signed Informed consent 16 . Inclusion Women Minorities 17 . RT : Patient must complete treatment plan approve protocol review team 1 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( CHF ) , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 2 . Patients clinically significant pulmonary dysfunction , cardiomyopathy , history clinically significant CHF exclude . The exclusion patient active coronary heart disease discretion attend physician . 3 . Patients significant atelectasis CT definition gross tumor volume ( GTV ) difficult determine . 4 . &lt; 1000 cc tumor free lung . 5 . Tumor volume location require lung volumePTV &gt; 40 % receive &gt; 20 Gy ( V20 &lt; 40 % ) . 6 . Patients exudative , bloody , cytologically malignant effusion eligible . 7 . Pregnancy breast feeding ( Women childbearing potential eligible , must consent use effective contraception therapy least 3 month complete therapy ) 8 . Patients must uncontrolled active infection curable without treatment cancer . 9 . Patients history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 . 10 . Patient may receive investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Metastatic Stage IV NSCLC</keyword>
	<keyword>Limited Volume Stage IV Non-small Cell Lung Cancer</keyword>
</DOC>